Forest plot showing the odds of 5-year overall-survival rate among children with brain tumors treated with either PT or XRT. by Renáta Kiss-Miki (20760127)

Subjects:

Data_table_with_all_identified_articles_31-JAN-2025. by Renáta Kiss-Miki (20760127)

Subjects:

Forest plot showing the ratio of odds of grade 3 anemia (=event) among pediatric patients with brain tumors treated with either PT or XRT. by Renáta Kiss-Miki (20760127)

Subjects:

Correlation between relative amounts of lipid species and number of days since the onset of symptoms among COVID-19 cases. by Spela Kokelj (8356644)

(a) Comparison of the approximate solution with the exact solution for the example 1. by Lahoucine Tadoummant (21647670)

(a) Comparison of the approximate solution with the exact solution for the example 2. by Lahoucine Tadoummant (21647670)

SEM images of alkali-activated samples JW1 at a magnification of ×5000. by Liang Li (46069)

SEM images of alkali-activated samples JW3 at a magnification of ×5000. by Liang Li (46069)

Point load strength apparatus: (a) before modification; (b) after modification. by Hong Zhang (25820)

SEM images of alkali-activated samples JW1 at a magnification of ×5000. by Liang Li (46069)

SEM images of alkali-activated samples JW3 at a magnification of ×5000. by Liang Li (46069)

Frontier analysis findings: (A) A frontier analysis diagram based on Age-Standardized DALYs Rate (ASDR) and the SDI from 1990 to 2021. by Guanghui Yu (423945)

Estimated coefficients from the SARIMA model of new COVID-19 deaths assuming a gradual effect following the implementation of two ETSs and one executive order in Oregon. by Raul Cruz-Cano (3751321)

Difference in various variables with different PA level. by Zixia Bu (21475019)

Demographic information of participants. by Zixia Bu (21475019)

“…The longitudinal results showed a decreasing trend of negative correlation between AB and PA under T1-T3 stages (r = −0.29, r = −0.44, P < 0.01), and no significant change in the degree of negative correlation with HSK (r = −0.28, r = −0.35, P < 0.01). …”

Evogliptin attenuates the pyroptotic cell death of VSMCs during CER treatment by decreasing the pyroptotic-associated genes and GSDM-D cleavage efficiency <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

“…<p>(A) Bar graph showed EVO significantly decreased Lactate dehydrogenase (LDH) release in CER treated P_i‐induced VSMCs. …”

Development of alpha diversity across weeks towards a new TNF treatment for each IBD disease subtype. by Katrine Carlsen (5477300)

Subsidence space (a), (b), (c), (d), (f), and curve (e), (g) in the mining area (Republished from Desheng Xie under a CC BY license, with permission from Desheng Xie, original copy... by Desheng Xie (21439869)

Flowchart of the screening process. by Huixia Ren (500186)

“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”

Result of the AMSTAR-2 assessments. by Huixia Ren (500186)

“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”